These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 15494503)

  • 1. Complement inactivation by recombinant human C3 derivatives.
    Kölln J; Spillner E; Andrä J; Klensang K; Bredehorst R
    J Immunol; 2004 Nov; 173(9):5540-5. PubMed ID: 15494503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hybrid proteins of Cobra Venom Factor and cobra C3: tools to identify functionally important regions in Cobra Venom Factor.
    Hew BE; Wehrhahn D; Fritzinger DC; Vogel CW
    Toxicon; 2012 Sep; 60(4):632-47. PubMed ID: 22609532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Engineering of human complement component C3 for catalytic inhibition of complement.
    Kölln J; Bredehorst R; Spillner E
    Immunol Lett; 2005 Apr; 98(1):49-56. PubMed ID: 15790508
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional characterization of human C3/cobra venom factor hybrid proteins for therapeutic complement depletion.
    Fritzinger DC; Hew BE; Thorne M; Pangburn MK; Janssen BJ; Gros P; Vogel CW
    Dev Comp Immunol; 2009; 33(1):105-16. PubMed ID: 18760301
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A new low molecular-weight protein effector of human complement from the venom of the Central Asian cobra Naja naja oxiana].
    Kozlov LV; Soliakov LS; Zinchenko AA
    Bioorg Khim; 1984 Mar; 10(3):323-32. PubMed ID: 6567467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of intermolecular bonds between human factor B and Cobra Venom Factor important for C3 convertase stability.
    Hew BE; Pangburn MK; Vogel CW; Fritzinger DC
    Toxicon; 2020 Sep; 184():68-77. PubMed ID: 32526239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional analysis of Cobra Venom Factor/human C3 chimeras transiently expressed in mammalian cells.
    Kölln J; Matzas M; Jänner N; Mix T; Klensang K; Bredehorst R; Spillner E
    Mol Immunol; 2004 May; 41(1):19-28. PubMed ID: 15140572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cobra complement system: I. The alternative pathway of activation.
    Vogel CW; Müller-Eberhard HJ
    Dev Comp Immunol; 1985; 9(2):311-25. PubMed ID: 3894085
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A low molecular weight inhibitor of the alternative complement pathway. I. Its isolation from human urine and the reaction mechanism.
    Nagaki K; Matsumoto M; Kitamura H
    Immunology; 1980 Dec; 41(4):789-98. PubMed ID: 6450726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Formation of classical C3 convertase during the alternative pathway of human complement activation].
    Kozlov LV; Shibanova ED; Zinchenko AA
    Biokhimiia; 1987 Apr; 52(4):660-6. PubMed ID: 3647798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure and function of recombinant cobra venom factor.
    Kock MA; Hew BE; Bammert H; Fritzinger DC; Vogel CW
    J Biol Chem; 2004 Jul; 279(29):30836-43. PubMed ID: 15131128
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-complement activity of oleanolic acid: an inhibitor of C3-convertase of the classical complement pathway.
    Kapil A; Sharma S
    J Pharm Pharmacol; 1994 Nov; 46(11):922-3. PubMed ID: 7897600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oxiagin from the Naja oxiana cobra venom is the first reprolysin inhibiting the classical pathway of complement.
    Shoibonov BB; Osipov AV; Kryukova EV; Zinchenko AA; Lakhtin VM; Tsetlin VI; Utkin YN
    Mol Immunol; 2005 Jun; 42(10):1141-53. PubMed ID: 15829304
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulation of complement activity by vaccinia virus complement-control protein.
    McKenzie R; Kotwal GJ; Moss B; Hammer CH; Frank MM
    J Infect Dis; 1992 Dec; 166(6):1245-50. PubMed ID: 1431243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complement activity in normal rabbit bronchoalveolar fluid. Description of an inhibitor of C3 activation.
    Giclas PC; King TE; Baker SL; Russo J; Henson PM
    Am Rev Respir Dis; 1987 Feb; 135(2):403-11. PubMed ID: 3643768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inactivation of complement by recombinant human C3 derivatives.
    Spillner F; Kölln J; Bredehorst R
    Adv Exp Med Biol; 2006; 586():347-60. PubMed ID: 16893083
    [No Abstract]   [Full Text] [Related]  

  • 17. Recombinant cobra venom factor.
    Vogel CW; Fritzinger DC; Hew BE; Thorne M; Bammert H
    Mol Immunol; 2004 Jun; 41(2-3):191-9. PubMed ID: 15159065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Site-specific activation of the alternative pathway of complement. Synthesis of a hybrid molecule consisting of antibody and cobra venom factor.
    Parker CJ; White VF; Falk RJ
    Complement; 1986; 3(4):223-35. PubMed ID: 3643079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isolation and properties of a complement inhibitor from Naja haje venom, distinct from known anticomplementary factors in cobra venom.
    von Zabern I; Przyklenk H; Damerau B; Zimmermann B
    Scand J Immunol; 1981 Aug; 14(2):109-20. PubMed ID: 6914809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduction in alternative complement pathway mediated C3 conversion following burn injury.
    Bjornson AB; Bjornson HS; Altemeier WA
    Ann Surg; 1981 Aug; 194(2):224-31. PubMed ID: 7259350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.